Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-21-012075
Filing Date
2021-08-26
Accepted
2021-08-26 07:01:11
Documents
41
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 6-K rdhl-20210630x6k.htm   iXBRL 6-K 76438
2 EX-1 rdhl-20210630xex1.htm EX-1 294017
3 EX-2 rdhl-20210630xex2.htm   iXBRL EX-2 641136
4 GRAPHIC rdhl-20210630xex1001.jpg GRAPHIC 7013
  Complete submission text file 0001558370-21-012075.txt   3818457

Data Files

Seq Description Document Type Size
5 EX-101.SCH rdhl-20210630.xsd EX-101.SCH 52235
6 EX-101.CAL rdhl-20210630_cal.xml EX-101.CAL 46083
7 EX-101.DEF rdhl-20210630_def.xml EX-101.DEF 114755
8 EX-101.LAB rdhl-20210630_lab.xml EX-101.LAB 400423
9 EX-101.PRE rdhl-20210630_pre.xml EX-101.PRE 228393
10 EXTRACTED XBRL INSTANCE DOCUMENT rdhl-20210630x6k_htm.xml XML 559511
Mailing Address 21 HA'ARBA'A STREET TEL AVIV L3 64739
Business Address 21 HA'ARBA'A STREET TEL AVIV L3 64739 972-3-541-3131
RedHill Biopharma Ltd. (Filer) CIK: 0001553846 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-35773 | Film No.: 211208795
SIC: 2834 Pharmaceutical Preparations